α ly 6g 1a8

For blocking antibodies, mice were injected i.p. with 250µg of α−CD4 (GK1.5, BioXcell) or 200µg of α-IFNAR (MAR1.5A3, BioXCell) one day before receiving 100 PFU of BrightFlu followed by a second dose at day 4 post infection. For depleting antibodies, mice were injected i.p. with 250µg of α-Ly-6G (1A8, Biolegend) daily for 5 days starting from 1 day prior to BrightFlu. Poly(I:C) was injected intratumorally with 10µg of Poly(I:C)-Rhodamine in 10µl PBS. For intracellular IL-12 staining, mice were injected i.v. with 250µg of Brefeldin A (Invivogen) and tissues harvested 6hr post injection.

For zymosan uptake: pHrodo zymosan particles (50 μg/ml) was added to cells for 1 h or mitoSOX Red (2.5 μM) was added to cells for 20 min. Cells were washed with PBS and detached from culture plates using Accutase treatment at 37 °C for 15 min, before thorough pipetting. Cells were transferred to flow cytometry tubes and analysed by a BD LSRII or BD Fortessa flow cytometer for fluorescent analysis. Doublets and debris were gates out before quantification of median fluorescent intensities with FlowJo (FlowJo, LLC).
For apoptosis detection: Cells were transferred to flow cytometry tubes and analysed by a BD LSRII flow cytometer. Doublets were gates out before evaluation of % Annexin V⁺ 7AAD⁻ (apoptotic) and % Annexin V⁺ 7AAD⁺ (dead) with FlowJo (FlowJo, LLC) (Supplementary Fig. 10).
For purity checks: α-F4/80-Pacific blue/ Alexa Fluor 647 (BM8, Biolegend) or α-CD11b allophycocyanin-Cy7 (M1/70, Becton Dickinson) were used for pTRMØ, and α-Ly-6G (1A8, Biolegend) or CD11b allophycocyanin-Cy7 was used for bone marrow neutrophils (Supplementary Fig. 10).